International Projects

• Identification and characterization of the gene coding for a 24 kDa amastigote specific protein of Leishmania major- a putative vaccine subunit candidate (Supported by UNDP/World Bank/WHO , ID# 970556, $98,000) 

• Cocktail recombinant protein and DNA vaccination of cpa, cpb and gp63 against L. major (Supported by UNDP/World Bank/WHO, ID # 981134, $41,000) 

• Evaluation of immune responses against L. infantum cysteine proteinases in Kala-azar individuals and DNA vaccinated dogs. (supported by UNDP/World Bank/WHO, ID # A10115. $125,000) 

• Preparation of diagnostic kit using L. infantum C-terminal extension of tpe I cysteine proteinases for early detection of human visceral leishmaniasis (EMRO WHO, $12,000) 

• Immunotherapy study using the combination of dSLIM and Sodium stibogluconate (Sb) against Leishmania major infection in susceptible BALB/c mice (supported by MOLOGEN AG, 20,000Euros) 

• Contribution of human neutrophils in the development of protective immune responses during in vitro  Leishmania major infection (supported by Karolinska Institute, Pasteur Institute of Iran and Iran ministry of Health, 110,000 Euros)

Current Projects supported by Pasteur Institute of Iran

• Evaluation of IgG subclasses responses to different overlapping CTE peptides in active and recovered visceral leishmaniasis individuals (ID#230).

• Evaluation of combined DNA and protein vaccination of C terminal extension from cysteine proteinase type I against L. infantum infection in BALB/c mice (ID#239). 

• Comparison of DNA and recombinant protein vaccination with Signal peptidase type I of L. major in BALB/c mice (ID#218).